ReachRxResearch
Home
Research
Sign Up
Comparative efficacy and safety of pharmacological regimens for Mycobacterium avium complex pulmonary disease and bacteremia: A systematic review with separate network meta-analyses
Back to Research Hub
  1. Home
  2. Research Hub
  3. Comparative efficacy and safety of pharm…

Comparative efficacy and safety of pharmacological regimens for Mycobacterium avium complex pulmonary disease and bacteremia: A systematic review with separate network meta-analyses

Journal of Infection·October 4Open Access
Infectious DiseasesPractice changingMycobacterium Avium Complex BacteremiaMycobacterium Avium Complex Pulmonary DiseaseSystematic Review And Network Meta-AnalysisAntimycobacterial Combination TherapyInhaled AminoglycosideMacrolide AntibioticAdultArikayceAmikacin Liposome Inhalation SuspensionClofazimineEthambutolRifamycin

Summary

View source

What was studied

A systematic review with separate Bayesian random-effects network meta-analyses compared the efficacy (treatment success) and safety (treatment-emergent adverse events) of pharmacological regimens for MAC pulmonary disease (MAC-PD) and MAC bacteremia in adults, drawing on 26 studies (16 RCTs, 10 cohort studies; n=3,574) published up to August 2026.

Key findings

For MAC-PD, ALIS added to guideline-based therapy (ALIS_GBT) ranked highest for efficacy (SUCRA=0.974; OR 5.74, 95% CrI 3.45–9.87 vs. GBT alone) but also carried the highest TEAE risk (OR 3.62, 95% CrI 1.63–8.77 vs. GBT). For MAC bacteremia, GBT alone ranked highest for treatment success (SUCRA=0.849), while clofazimine-containing regimens were associated with significantly lower odds of success (clofazimine + rifamycin/ethambutol/fluoroquinolone: OR 0.18, 95% CrI 0.09–0.33; clofazimine + macrolide: OR 0.52, 95% CrI 0.27–0.97).

Study limitations

Substantial heterogeneity was observed for treatment success outcomes in both disease networks; evidence was sparse for several comparisons; safety reporting was variable across studies; and transitivity assumptions may not fully hold given differences in patient populations and disease manifestations across studies.

Clinical implications

ALIS added to guideline-based therapy is a potent but adverse-event-prone option best reserved for refractory or difficult-to-treat MAC pulmonary disease. In MAC bacteremia, clinicians should favor standard guideline-based therapy over clofazimine-containing regimens, which showed meaningfully worse treatment success in this analysis.

Caveats

  • Evidence for several regimen comparisons is sparse, meaning some credible intervals are wide and estimates may be unstable
  • Most MAC bacteremia data likely originate from HIV-era studies; applicability to contemporary immunocompromised or non-HIV populations may be limited
  • Substantial heterogeneity in treatment-success outcomes across both MAC-PD and MAC bacteremia networks limits the precision and generalizability of rankings
Show all 4
  • The analysis pools RCTs and cohort studies, which may introduce confounding and differences in outcome definitions affecting treatment-success estimates

Related Questions

Explore related topics

What is the role of amikacin liposome inhalation suspension (ALIS) in refractory MAC pulmonary disease?How does guideline-based therapy compare to clofazimine regimens in MAC bacteremia treatment?What are the adverse effects and monitoring strategies for ALIS in non-tuberculous mycobacterial lung disease?

Publication Details

Year
2026
Journal
Journal of Infection
Sample Size
n=3,574
Source
View article
Keep scrolling
More content below.
Up Next